Zobrazeno 1 - 10
of 50
pro vyhledávání: '"B L, Andersen"'
Autor:
O. B. Brodnicke, M. R. Jensen, P. F. Thomsen, T. Brorly, B. L. Andersen, S. W. Knudsen, K. Præbel, S. J. Brandl, M. J. Sweet, P. R. Møller, K. Worsaae
Publikováno v:
Environmental DNA, Vol 6, Iss 3, Pp n/a-n/a (2024)
Abstract Coral reefs represent some of the most biodiverse ecosystems in the world but are currently undergoing large‐scale degradation due to anthropogenic stressors. Such degradation usually begins with coral bleaching, and if the stress conditio
Externí odkaz:
https://doaj.org/article/81870658cca84152be4f54f34a44ccee
Autor:
Stylianos Georgiadis, Kamilla Danebod, Jolanta Grydehøj, Merete Lund Hetland, Johnny Lillelund Raun, Stavros Chrysidis, Salome Kristensen, Charlotte Wiell, Bente Glintborg, Natalia Manilo, Anders Villumsen, Hanne Merete Lindegaard, Dorte Vendelbo Jensen, Frank Mehnert, Mette Nørgaard, Anne Gitte Loft, Niels Steen Krogh, Grith Eng, Oliver Hendricks, Asta Linauskas, B. L. Andersen
Publikováno v:
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G R, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Lange Andersen, B, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J L, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, bind 79, nr. 6 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : An observational nationwide study applying linkage between DANBIO and national registries ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G R, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Lange Andersen, B, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J L, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, bind 79, nr. 6 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : An observational nationwide study applying linkage between DANBIO and national registries ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Recent international guidelines recommend the use of biosimilar biological drugs on similar terms as their corresponding originators, including switching from a bio-originator to the biosimilar.1 However, the comparative safety of biosimilars in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67904a17aae6d2a100c9d8e44060c0e
https://vbn.aau.dk/da/publications/1af94544-8bca-444e-aa8a-980b51288dff
https://vbn.aau.dk/da/publications/1af94544-8bca-444e-aa8a-980b51288dff
Autor:
L.S. Andersen, Hanne Merete Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Oliver Hendricks, Asta Linauskas, Dorte Dalsgaard Pedersen, B. L. Andersen, Henrik Nordin, Anne Gitte Loft, Salome Kristensen, Inge Juul Sørensen, Inger Marie Jensen Hansen, Frank Mehnert, Jakob Espesen, Emina Omerovic, Kamilla Danebod, E. B. Dalsgaard, B. Glintborg, Niels Steen Krogh, Jolanta Grydehøj, Stavros Chrysidis, D V Jensen, Johnny Lillelund Raun, Merete Lund Hetland
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background In Denmark, patients (pts) treated with originator etanercept (ETA) 50 mg SC conducted a mandatory non-medical switch to biosimilar SB4 in April 2016 (switchers). Pts treated with 25 mg ETA or 50 mg powder-solution were not mandated to swi
Autor:
Dorte Dalsgaard Pedersen, Emina Omerovic, Kamilla Danebod, Johnny Lillelund Raun, L.S. Andersen, Dorte Vendelbo Jensen, Natalia Manilo, Merete Lund Hetland, Anne Gitte Loft, Niels Steen Krogh, Oliver Hendricks, Hanne Merete Lindegaard, Asta Linauskas, Henrik Nordin, Inger Marie Jensen Hansen, Jakob Espesen, Susanne Højmark Jakobsen, Salome Kristensen, Frank Mehnert, B. L. Andersen, Inge Juul Sørensen, E. B. Dalsgaard, Stavros Chrysidis, Bente Glintborg, Jolanta Grydehøj
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background In Denmark, rheumatoid arthritis(RA), psoriatic arthritis(PsA) and axial spondyloarthritis(AxSpA) patients (pts) treated with originator etanercept (ETA) 50 mg SC conducted a mandatory non-medical switch to biosimilar Etanercept (SB4) in A
Autor:
Anne Gitte Loft, Dorte Vendelbo Jensen, Jolanta Grydehøj, Merete Lund Hetland, Oliver Hendricks, Natalia Manilo, Asta Linauskas, Inger Marie Jensen Hansen, Jakob Espesen, Johnny Lillelund Raun, Henrik Nordin, Stavros Chrysidis, Salome Kristensen, Lis Smedegaard Andersen, Inge Juul Sørensen, Sabine Sparre Dieperink, Bente Glintborg, Krogh Niels Steen, B. L. Andersen, Mohammad Hossein, Kamilla Danebod, Dorte Dalsgaard Pedersen, Hanne Merete Lindegaard, Emil Barner Dalgaard
Publikováno v:
Poster Presentations.
Background In Denmark, biological drugs are provided free by the hospitals to the patients via a tax-based system. In 2015 a non-medical switch from originator infliximab to CT-P13 was conducted (1). According to national guidelines in April 2016, a
Autor:
Cato Mork, S. Kroon, Gregor B.E. Jemec, K. M. Brocks, Ida Marie Stender, Kristina S Ibler, Hans Christian Wulf, Susanne Fabricius, Carin Sandberg, Peter A. Philipsen, Monika Gniadecka, Merete Haedersdal, B. L. Andersen, Jakob Heydenreich, S.R. Wiegell, Berit Berne
Publikováno v:
British Journal of Dermatology. 166:1327-1332
Summary Background Photodynamic therapy (PDT) is an attractive therapy for nonmelanoma skin cancers and actinic keratoses (AKs). Daylight-mediated PDT is a simple and tolerable treatment procedure for PDT. Methyl aminolaevulinate (MAL)-PDT is approve
Autor:
D. C. Ihde, A. M. Fremgen, J. M. Cain, D. Lowy, M. R. Henry, A. H. Epstein, B. L. Andersen, J. R. Lunney, P. W. Grigsby, D. K. Ash, J. Ruffin, M. H N Tattersall, M. F. Mitchell, H. W. Lawson, Frederick Stehman, R. C. Park, C. McNeil, P. J. Hitchcock, B. S. Kramer, J. F. Magrina, J. M. Elliott, M. A. Penalver, W J Jr Spanos, A. S. Lichter, R. S. Berkowitz, R. M. Lanciano, P. E. Saigo, J. H. Ferguson, I. Gage, M. A. Steller, C. Nichols, P. S. Braly, Carol L. Brown, C. P. Hunter, R. L. Sweet, J. L. Bader, M. E. Randall, K. D. Hatch, W. H. Hall, V. W. Pinn, J. Overgaard, G L Sr Eddy, A. H. Rusell, D. Kapp, G. A. Omura, A. E. Howes, M. Morris, D. G. Petereit, J. A. Benda, J. S. Hutchison, P. J. Eifel, A. F. Saftlas, R. Herrero, H. M. Keys, S. Scherr, N. Munoz, G. M. Thomas
Publikováno v:
Gynecologic Oncology. 66:351-361
Autor:
B. L. Andersen
Publikováno v:
Global Biogeochemical Cycles. 10:191-196
The derivation and use of a general formula for calculating the isotopic composition paramater in a system with any number of sources and sinks is presented in this paper. The formula is generally applicable to laboratory experiments with the purpose
Autor:
S R, Wiegell, S, Fabricius, M, Gniadecka, I M, Stender, B, Berne, S, Kroon, B L, Andersen, C, Mørk, C, Sandberg, K S, Ibler, G B E, Jemec, K M, Brocks, P A, Philipsen, J, Heydenreich, M, Hædersdal, H C, Wulf
Publikováno v:
The British journal of dermatology. 166(6)
Photodynamic therapy (PDT) is an attractive therapy for nonmelanoma skin cancers and actinic keratoses (AKs). Daylight-mediated PDT is a simple and tolerable treatment procedure for PDT. Methyl aminolaevulinate (MAL)-PDT is approved for the treatment
Autor:
S R, Wiegell, S, Fabricius, I M, Stender, B, Berne, S, Kroon, B L, Andersen, C, Mørk, C, Sandberg, G B E, Jemec, M, Mogensen, K M, Brocks, P A, Philipsen, J, Heydenreich, M, Haedersdal, H C, Wulf
Publikováno v:
The British journal of dermatology. 164(5)
Actinic keratoses (AKs) are common dysplastic skin lesions that may differentiate into invasive squamous cell carcinomas. Although a superior cosmetic outcome of photodynamic therapy (PDT) is advantageous compared with equally effective treatments su